Boehringer Ingelheim Vetmedica, Inc. (BIVI) has a strong foundation of innovative biological and pharmaceutical research and development, manufacturing and technical service. And, the company takes pride in keeping those service operations close at hand in facilities that are owned and operated in the U.S. by Boehringer Ingelheim Vetmedica, Inc.

In 2009, Boehringer Ingelheim Vetmedica, Inc. significantly increased the size of its animal health division with the addition of several cattle product lines and substantial manufacturing assets in Fort Dodge, Iowa. This was done through the acquisition of selected assets that were formerly part of Fort Dodge Animal Health. And, this year BIVI is taking the final step to integrate all of those new products into its production chain.

“Boehringer Ingelheim Vetmedica, Inc. is expanding its state-of-the-art biological GMP manufacturing facility in St. Joseph, Missouri, to accommodate the significant global increase in demand for animal health products,” says Colin Meyers, executive director of U.S. Cattle Business and Process Excellence, Boehringer Ingelheim Vetmedica, Inc. “We are excited because, with this expansion, BIVI is increasing the size of the plant by more than 50 percent.”

Upon completion of the expansion to the facility, Boehringer Ingelheim Vetmedica, Inc. will be producing several more cattle vaccine product lines at the St. Joseph facility. This will move products including Presponse, TrichGuard, TriVib, Triangle, Pyramid, Prism and EnterVene by the end of 2011. In fact, the antigen production capacity will be increasing by 80 percent, with 50 percent going to the manufacture of cattle biological products.

Additional expansion will increase capacity in several other areas:
• 20 percent in growth-media preparation;
• 100 percent in antigen blending;
• 20 percent in final-product filling. PD

—From Boehringer Ingelheim Vetmedica news release